ABSTRACT. Vitronectin is a cell-adhesive glycoprotein present in animal blood and extracellular matrix. To establish the molecular basis of vitronectin interactions with extracellular matrix macromolecules, the binding site of vitronectin to collagen has been investigated. Vitronectin fragments obtained by formic acid cleavage were separated by heparin-affinity chromatography followed by gel filtration chromatography. The collagenbinding activity of the fragments was assayed in terms of inhibitory activity on the binding of 125I-vitronectin to immobilized collagen. There were two groups of collagen-binding fragments. One group consisted of 5 heparinbinding fragments with estimated molecular masses of 12 kDa, 14 kDa, 16 kDa, 18 kDa, and 19 kDa in SDSpolyacrylamide gel electrophoresis.
Vitronectin is a cell-adhesive glycoprotein present in animal blood and extracellular matrix (for reviews, see [1] [2] [3] . Vitronectin in animal sera or in physiological salt solution spontaneously deposits on the surface of tissue culture dishes in vitro, attaches cells to the substratum, changes the shape of the cells (4) (5) (6) , and promotes cell migration (7, 8) . The principal active site is a tripeptide, Arg-Gly-Asp, located close to the NH2-terminus of vitronectin (9, 10) . Cell surface vitronectin receptor, mainly integrin ayft, interacts with vitronectin through this tripeptide (ll, 12) . Treatment of melanoma cells with anti-integrin aYp3 antibodies results in stimulation of both secretion and transcription of type IV collagenase (13) . Therefore, the vitronectin-integrin ayft system seems to be a cell-surface regulatory system for attachment, shape, migration, secretion, and gene expression of cells. At a higher level, this system itself is regulated by soluble factors such as tumor necrosis factor a, interferon y9 and transforming growth factor-/31 (14, 15) . In addition, vitronectin plays a role in the regulation of blood coagulation and complement-mediated cytolysis in the soluble phase (for reviews, see 1, 2) . Immunohistochemical studies have revealed vitronectin deposits in loose connective tissues of skeletal muscle, embryonal lung, fetal membrane, and kidney (16, 17) . Vitronectin is also found in vascular wall (18) and around elastic fibers in normal skin (19) as well as skin from patients with elastic tissue disorders (20). In huTo whomcorrespondence should be addressed. mancancer patients, vitronectin is enriched in the stroma of breast and colon carcinomas (21) and in the parenchyma of glioblastoma tumor (22).
There should be macromolecules responsible for the deposition of vitronectin on tissue extracellular matrix. Glycosaminoglycans are likely candidates, since heparin strongly binds to vitronectin (16, 23, 24) . Tissue type glycosaminoglycans including chondroitin sulfate, dermatan sulfate, hyaluronan, heparan sulfate, and keratan sulfate do not, however, seem to bind vitronectin (23, 24) . On the other hand, Gebb et al. (25) reported that purified vitronectin binds to native collagen in vitro. The binding is quite strong, although it is inhibited by high salt concentration, and nothing is yet knownabout the colocalization of vitronectin with collagen in vivo. Endogenous plasma/serum vitronectin does not bind to collagen. Specific activating conditions, such as boiling after the addition of 8 Murea and heparin (26), are necessary for the acquisition of collagen-binding activity. Therefore, the physiological meaning of the collagen-binding ability of vitronectin is uncertain. But collagen-binding seems to be one of the essential properties of vitronectin, since various purified animal blood vitronectins, except chick yolk vitronectin (27) , bind to collagen (28).
Therefore, we decided to probe the in vitro interaction of vitronectin with collagen by isolating the collagen-binding fragments of vitronectin, in order to clarify the collagen-binding site of vitronectin and to provide tools to investigate further the molecular basis of the in-teraction between vitronectin and collagen.
MATERIALS AND METHODS
Vitronectin and vitronectin fragments. Vitronectin was purified from human outdated plasma according to Yatohgo et al. (29) . Purified vitronectin was extensively dialyzed against 10 mMNH4HCO3 and then lyophilized. Vitronectin (17.2 mg) was cleaved with 17 ml of 70% formic acid at 50°C for 16 h according to Suzuki et al. (30) . Formic acid was removedby lyophilization after addition of 9 vol of distilled water. The vitronectin fragments were taken up in 0.13 M NaCl, 8 M urea, 5 mMEDTA, 10mM^8-mercaptoethanol, and 10 mMNa-phosphate buffer (pH 7.7), and applied to a heparin-Sepharose 4B column (5 ml bed volume). The flowthrough fractions were collected, then heparin-binding fragments were eluted from the column with 0.5 MNaCl, 8M urea, 5 mMEDTA, 10 mM/3-mercaptoethanol, and 10 mM Na-phosphate buffer (pH 7.7). Both heparin-binding and -nonbinding fragments were concentrated and fractionated by gel filtration on a column of Sephacryl S-200 (16 mmx 94 cm) in 0.05 MNaCl, 8 M urea, 5 mMEDTA, 10 mM/3-mercaptoethanol, and 10 mMNa-phosphate buffer (pH 7.7) at a flow rate of 0.065 ml/min/cm2 at room temperature. Collagen-binding assay. Binding of vitronectin to collagen was measured by using 125I-labeled vitronectin and microtiter plates bearing immobilized collagen as described previously (3 1). Collagen-binding ability of vitronectin fragments was assayed in terms of inhibitory activity on the binding of 125I-labeled whole vitronectin to collagen. Briefly, native type I collagen from porcine skin (Nitta Gelatin, Osaka, Japan) was incubated at a concentration of 10 //g/ml in 96-well soft microtiter plates made of polyvinyl chloride at 4°C overnight. The plates were rinsed, and blocked with 0.2% skim milk. Fifty fil of 125I-labeled vitronectin in 0.05% Tween-20 and 10 mMNaphosphate buffer (pH 7.4) was then added to each well. To examine the collagen-binding activity of vitronectin fragments, the fragments (0-50 fig/ml) were mixed with 0.5 /^g/ml of 125I-labeled vitronectin at this step. To examine the activity of Sephacryl S-200 fractions, each fraction was diluted to 1/20 with 0.05% Tween-20 and 10 mMNa-phosphate buffer (pH 7.4) after dialysis against 8 Murea, 5 mMEDTA, and 10 mM Na-phosphate buffer (pH 7.4). After incubation at 37°C for 1 h, the plates were rinsed 4 times with 0.05% Tween-20 and 10 mMNa-phosphate buffer (pH 7.4), and cut into individual wells with scissors. The radioactivity that remained in each well was counted with a gammacounter, Aloka ARC-500.
RESULTS
Vitronectinfragmentation and collagen-binding. Vitronectin (a mixture of 75 kDa and 65 kDa; Fig. 1 , lane 1) was cleaved by 70% formic acid into many fragments ranging in size from 12 kDa to 70kDa (Fig. 1, lane 2) . Formic acid fragments of vitronectin interfered with the binding of 125I-labeled vitronectin to collagen, though they were several fold less active than intact vitronectin (Fig. 2) . Thus, these fragments retained their collagenbinding activity. Vitronectin fragments were separated by heparin-affinity chromatography into heparin-nonbinding fragments (Fig. 1 , lane 3) and heparin-binding fragments (Fig. 1, lane 4) heparin-nonbinding and -binding fragments were examined for their ability to interfere with 125I-labeled vitronectin binding to collagen. The mixture of heparin-binding fragments had activity as strong as that of intact vitronectin. The mixture of heparin-nonbinding fragments also had similar, but weaker, activity (Fig. 2 ).
Collagen-binding of heparin-binding fragments.
Heparin-binding fragments were fractionated by gel filtration chromatography on Sephacryl S-200 in the pre- sence of 8 Murea. Each fraction was tested for ability to interfere with the binding of 125I-labeled vitronectin to collagen, as well as protein concentration. There was an interfering activity around fraction number 77, which corresponded to the third peak of the elution profile in terms of absorbance at 280 nm (Fig. 3) . SDS-polyacrylamide gel electrophoresis of serial fractions from 70 to 82 revealed several bands (Fig. 4) . The profile of the activity in Fig. 3 corresponds well to the appearance of 5 bands of less than 19 kDa in Fig. 4 . Their molecular masses were 12kDa, 14kDa, 16kDa, 18kDa, and 19 kDa. These results suggest that one collagen-binding site of vitronectin is contained in these five heparin-binding fragments.
Collagen-binding of heparin-nonbinding fragments. Heparin-nonbinding fragments were similarly fractionated by gel filtration chromatography. Five major fractions were pooled and examined for collagen-binding activity and for polypeptide composition by SDS-polyac-0.050. 5 5 50 PROTEIN ( M9/ml) rylamide gel electrophoresis. Fractions 4 and 1 had relatively strong activity and fraction 2 had weak activity, while fractions 3 and 5 had no activity (Fig. 5A ). Fraction 4 contained mainly an 18 kDa polypeptide and fraction 1 contained only a 40kDa band, which was also present in fraction 2 (Fig. 5B) . These results suggest that active fragments among the heparin-nonbinding fragments are those with molecular masses of 40 kDa and 18 kDa.
DISCUSSION
Wehave identified several vitronectin fragments which interfere with the binding of 125I-whole vitronectin to immobilized collagen. Vitronectin fragments produced by 70% formic acid were previously mapped by Suzuki et al. (30) , who concluded that the heparin-nonbinding 40 kDa and 18 kDa fragments are located in the NH2-terminal half, while the heparin-binding [12] [13] [14] [15] [16] [17] [18] [19] kDa fragments are located in the COOH-terminal half of vitronectin. The heparin-nonbinding 40 kDa fragment almost entirely spans the NH2-terminal half and includes the heparin-nonbinding 18 kDa fragment, but it does not share any region with the heparin-binding 12-19 kDa fragments. Therefore, there should exist two collagen-binding sites (site 1 and site 2) in vitronectin, as
shown in a structural model of vitronectin (Fig. 6) , in which site 1 may be located near the NH2-terminus or in the central part of the molecule. Figure 6 also presents a plausible mappingof all the vitronectin fragments referred to in this report. Wepreviously showed that one collagen-binding site is located in the NH2-terminal half of the molecule on the basis of inhibition analysis of collagen-binding by monoclonal antibodies (31). The NH2-terminal collagen-binding site identified by use of the monoclonal antibodies seems to correspond to site 1 in this report.
Site 2, reported here for the first time, is located near the heparin-binding region of vitronectin. This site was active in smaller, but not larger, fragments (Fig. 3) . Because of the vicinity of site 2 to the heparin-binding site, the larger fragments should contain site 2 according to the mapping by Suzuki et al. (30) . It is not clear why the collagen-binding activity of site 2 is detected in smaller, but not larger, fragments. One possibility is that site 2 is cryptic in the larger fragments but is exposed at the mo- 
